CSTL 241115 22.50C (CSTL241115C22500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

CSTL241115C22500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 4 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Castle Biosciences Inc : Leerink Partners Raises Target Price to $50 From $45
Reuters50minutes ago
Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript Summary
moomoo AI20:03 ET · Conference Call
Castle Biosciences | 10-Q: Quarterly report
SEC16:14 ET · Announcements
Express News | Castle Biosciences Inc FY2024 Rev View $298.0 Mln -- LSEG IBES Data
Reuters16:09 ET
Express News | Castle Biosciences Inc: Raising Full-Year 2024 Revenue Guidance to $320-330 Mln
Reuters16:08 ET
Castle Biosciences Q3 2024 GAAP EPS $0.08 Beats $(0.03) Estimate, Sales $85.800M Beat $79.842M Estimate
Benzinga16:08 ET

Comments

Stock_Drift

Oct 20 04:18

$Castle Biosciences (CSTL.US)$

Teddy123

Sep 29 21:15

New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients w

$Castle Biosciences (CSTL.US)$
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma | CSTL Stock News

Bigmoney Dreamer

Sep 3 11:38

$Castle Biosciences (CSTL.US)$

Bigmoney Dreamer

Aug 30 11:51

$Castle Biosciences (CSTL.US)$

Trytosaveabit

May 29 15:33

Nice!

$Castle Biosciences (CSTL.US)$ New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis 1 MINUTE AGO, 4:30 PM EDT VIA BUSINESSWIRE